Dimensional Fund Advisors LP raised its position in Gilead Sciences Inc. (NASDAQ:GILD) by 1.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,034,616 shares of the biopharmaceutical company’s stock after buying an additional 33,533 shares during the period. Dimensional Fund Advisors LP owned approximately 0.23% of Gilead Sciences worth $253,128,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in GILD. Joel Isaacson & Co. LLC raised its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Jolley Asset Management LLC raised its position in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares during the last quarter. Loomis Sayles & Co. L P raised its position in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the last quarter. North Star Investment Management Corp. raised its position in Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares during the last quarter. Finally, Stanley Laman Group Ltd. purchased a new position in Gilead Sciences during the second quarter valued at about $205,000. Institutional investors and hedge funds own 77.94% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 1.62% during midday trading on Friday, hitting $79.12. The stock had a trading volume of 11,031,540 shares. The company’s 50-day moving average price is $79.40 and its 200-day moving average price is $85.53. The firm has a market cap of $104.41 billion, a price-to-earnings ratio of 6.94 and a beta of 1.06. Gilead Sciences Inc. has a 12-month low of $76.67 and a 12-month high of $111.11.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period last year, the company posted $3.15 EPS. Equities research analysts forecast that Gilead Sciences Inc. will post $11.76 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 16.56%.
GILD has been the topic of several research reports. Robert W. Baird reissued an “outperform” rating and set a $135.00 target price on shares of Gilead Sciences in a research note on Monday, June 6th. Morgan Stanley reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, June 6th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, June 8th. Leerink Swann reissued a “buy” rating and set a $120.00 target price (down previously from $123.00) on shares of Gilead Sciences in a research note on Thursday, June 9th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, June 13th. Ten investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $105.00.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the completion of the transaction, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at approximately $98,747,309.79. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total value of $409,200.00. Following the transaction, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.